STAT+: Intellia’s CRISPR-based treatment dramatically reduced patients’ swelling attacks in small trial
Intellia Therapeutics said Saturday that the first 10 patients to receive a CRISPR-based treatment for…
Category: biotechnology
STAT+: With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment
CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a…
.jpg)
STAT+: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
STAT+: With expectations rising, Corbus reveals new data on its ADC bladder cancer treatment
CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor…
FDA approves Moderna’s RSV vaccine, its second licensed product
The Food and Drug Administration on Friday approved Moderna’s vaccine to protect older adults against…
The surprising outperformance of a new drug against existing competitors, and other biotech updates
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Ionis drug prevents swelling attacks caused by rare genetic disease in late-stage trials
Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on…
STAT+: Ultragenyx gene therapy for rare liver ailment succeeds in late-stage trial
Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease…
Listen: An ASCO preview & another Duchenne trial failure
Which presentations are worth catching at ASCO this weekend? What is exon-skipping? And how do…
STAT+: Did Sarepta Therapeutics earn $4 billion from exon-skipping drugs that don’t work?
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
Biohaven’s autoimmune drug disappoints, and other biotech news updates from the week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biohaven protein-degrader drug falls short of investor expectations in early-study test
Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a…
Wegovy linked to lower risk of alcohol use disorder in real-world study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Reports: Looking to expand its pipeline, Merck to buy eye-disease startup EyeBio
LONDON — Merck is buying ophthalmology-focused startup EyeBio in a deal worth up to $3…
Biotech’s most interesting fundraisings from the last week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Airway disease drug from Insmed succeeds in one of the year’s most anticipated trials
An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway…
STAT+: Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer
Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor…
STAT+: Japanese conglomerate to buy Calliditas Therapeutics, maker of a kidney disease drug
LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is…
STAT+: ASCO preview: a promising solid tumor CAR-T, an AI patient navigator, and improving palliative care
Thousands of cancer researchers and clinicians are flocking to Chicago for the American Society of…
More tumult at BIO amid the company’s fourth CEO in four years
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: FDA advisers endorse Guardant Health’s colon cancer screening test
An independent panel of advisers to the Food and Drug Administration recommended the agency approve…
STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical
An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some…
STAT+: Pharma’s losing bet in New Jersey
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again, and other thoughts
Thoughts about Cytokinetics after Wednesday night’s financing announcement: 1. Management is raising $500 million at…
STAT+: Biotechs turn to gene silencing for obesity drugs that can last longer than Wegovy
Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a…
STAT+: Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575 million, lowering hopes of a buyout
Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called…
STAT+: FDA poised to publish guidelines for clinical trial diversity
The Food and Drug Administration is poised to tell drug and medical device makers how…
Maryland takes first steps to cap drug costs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biogen joins immunology wave with $1.15 billion acquisition
Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a…
Listen: A conversation with researcher Kevin Esvelt on the urgency of improving biosecurity measures
If you ask a chatbot how to cause a pandemic, it will suggest the 1918…
STAT+: At a flashy new research hub, AstraZeneca lays out ambitious growth goals
CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious…
Lilly doubles down on radiopharma
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: AltruBio raises $225 million to develop ulcerative colitis drug and other immune checkpoint enhancers
Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have…
STAT+: GSK’s asthma push continues as drug succeeds in Phase 3 trials
A new asthma treatment that could be administered just once every six months has succeeded…
STAT+: Amid acquisition speculation, Cytokinetics CEO stresses company can launch heart drug on its own
As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage…
AstraZeneca antibody reduced Covid-19 risk in immunocompromised
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Live! From the STAT Breakthrough Summit West
On this week’s “Readout LOUD,” we’re live in San Francisco at STAT’s Breakthrough Summit West….
STAT+: NVIDIA’s Kimberly Powell touts progress on AI in drug discovery
SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by…
STAT+: PDS Biotech’s survival benefit is absurdly overstated
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Biogen, Ionis drop ALS treatment after study failure
A plan to use new genetic techniques to treat non-genetic forms of ALS failed in…
Blackstone wants in on red-hot immunology market
The need-to-know this morning Biogen and Ionis Pharmaceuticals are ending their development of an experimental drug for ALS based on…
STAT+: Galapagos, in makeover mode, strikes deal to make CAR-T therapies at blood centers across U.S.
Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday…
STAT+: WuXi Biologics execs register to lobby as Congress comes for the company
WASHINGTON — WuXi Biologics executives have joined the lobbying fray in the lead-up to a…
Leqembi gets closer to being offered as an injection
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Is Novavax a new meme stock?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Late-stage results set up Cytokinetics heart drug to compete with Bristol
Late-stage results of Cytokinetics’ drug for a rare heart disease suggest it can compete with…
We now know Tome’s gene editing target
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Can AI build custom ‘n-of-1’ drugs faster? Maybe not yet, new case study suggests
Two years ago, Yiwei Shi was searching desperately for someone to build a drug for…
The public wants Medicare to cover obesity drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…